The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | HRQoL in patients with transplant-ineligible NDMM treated with Isa-VRd in the IMROZ study
In this video, Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, shares updated results from the IMROZ trial (NCT03319667), highlighting the health-related quality of life (HRQoL) measurements in patients with newly diagnosed multiple myeloma (NDMM) treated with Isa-VRd (isatuximab, bortezomib, lenalidomide, and dexamethasone). This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
